VANCOUVER, BC, Sept. 20, 2022 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life“) announces that the board of directors of the Company (the “Board“), on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due.


Previous articleMindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
Next articleAlgernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program